[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368928-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368928-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-body-mass-index-in-determining-the-efficacy-of-nivolumab-for-patients-with-advanced-non-small-cell-lung-cancer","The Role of Body Mass Index in Determining the Efficacy of Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer","","Background: Non-small cell lung cancer (NSCLC) has poor prognosis, and immune checkpoint inhibitors such as nivolumab improve outcomes; however, the influence of body mass index (BMI) on immunotherapy efficacy remains uncertain. Methods: A retrospective study included 300 metastatic NSCLC patients receiving nivolumab monotherapy from January 2020 to March 2025, assessing overall survival as the primary endpoint. Results: Median overall survival and progression-free survival were 8.76 and 3.63 months, with no significant BMI-group differences. Conclusions: BMI showed no prognostic value for OS or PFS; ECOG PS≥2 and older age were unfavorable.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-body-mass-index-in-determining-the-efficacy-of-nivolumab-for-patients-with-advanced-non-small-cell-lung-cancer/368928/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-body-mass-index-in-determining-the-efficacy-of-nivolumab-for-patients-with-advanced-non-small-cell-lung-cancer/368928.png","ImageObject",300,407,{"name":42,"@type":43},"Guten tag","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about BMI and nivolumab?","Question",{"text":63,"@type":64},"The study evaluates whether body mass index (BMI) is associated with treatment efficacy of nivolumab monotherapy in advanced NSCLC patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected and what were the primary and secondary endpoints?",{"text":68,"@type":64},"The retrospective analysis included 300 metastatic NSCLC patients treated with nivolumab between January 2020 and March 2025. Overall survival was the primary endpoint, with progression-free survival, treatment response, and toxicity as secondary endpoints.",{"name":70,"@type":61,"acceptedAnswer":71},"Did BMI affect overall survival or progression-free survival?",{"text":72,"@type":64},"No. Median overall survival and progression-free survival did not differ significantly between BMI groups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368928,1790869865,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","CLINICAL RESEARCH  \ne-ISSN 1643-3750  \n© Med Sci Monit, 2025; 31: e951296 DOI: 10. 12659/MSM.951296  \nReceived: 2025.08.27  \nAccepted: 2025.09.29  \nAvailable online: 2025.10.04  \nPublished: 2025.10.14  \nAuthors’ Contribution: Study Design A  \nData Collection B Statistical Analysis C Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G  \nACDEF ABEF  \nBC  \nCorresponding Author: Financial support: Conflict of interest:  \n1 1  \n2  \nThe Role of Body Mass Index in Determining the Efficacy of Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer  \nBilgin Demir  Gökhan Çolak İrem Aşık Bal  \nBilgin Demir, e-mail: [bilgin287@hotmail.com](bilgin287@hotmail.com)  \nNone declared  \nNone declared  \n1 Department of Medical Oncology, Aydin Adnan Menderes University, Aydın, Türkiye  \n2 Department of Internal Medicine, Aydin Adnan Menderes University, Aydın, Türkiye  \nBackground: Non-small cell lung cancer (NSCLC) comprises 85% of lung cancers with poor prognosis. Immune checkpoint inhibitors (ICIs), particularly nivolumab, show survival benefits in advanced NSCLC. The effect of body mass index (BMI) on immunotherapy outcomes remains controversial. This study investigated the relationship between BMI and treatment outcomes in advanced NSCLC patients treated with nivolumab monotherapy.  \nMaterial/Methods: A retrospective analysis at Aydın Adnan Menderes University included 300 metastatic NSCLC patients treated with nivolumab between January 2020 and March 2025. Patients under age 18 years, lacking pathology confirmation, receiving combination therapies, or with BMI \u003C18.5, were excluded. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), treatment response, and toxicity. BMI was categorized as \u003C25 kg/m2 and ³25 kg/m2. Survival outcomes were analyzed using Kaplan-Meier and Cox regression analyses.  \nResults: Of 300 patients, 53.3% had BMI \u003C25 and 46.7% had BMI ³25. Median OS and PFS were 8.76 and 3.63 months, respectively, with no significant differences between BMI groups (p>0.05). PD-L1 expression ³50% was associated with reduced progression risk. ECOG PS ³2, age >65, and liver metastases negatively impacted survival. An increased number of nivolumab cycles improved OS and PFS. The objective response rate was 31.6%. Common adverse events were fatigue (25%), nausea (23.7%), and hypothyroidism (18%), without BMI-related variation.  \nConclusions: The study found no evidence supporting BMI as a prognostic factor for OS or PFS in advanced NSCLC patients treated with nivolumab. ECOG PS ³2 and older age were poor prognosis indicators. BMI should be evaluated as a continuous variable. Further studies are needed to clarify obesity’s role in immunotherapy responses.  \nKeywords: Body Mass Index • Carcinoma, Non-Small-Cell Lung • Immune Checkpoint Inhibitors  \nFull-text PDF: [https://www.medscimonit.com/abstract/index/idArt/951296](https://www.medscimonit.com/abstract/index/idArt/951296)  \n3518  3  2  22  \nPublisher’s note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher  \nThis work is licensed under Creative Common AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)  \ne951296-1  \nIndexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System][ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica][Chemical Abstracts/CAS]  \nCLINICAL RESEARCH  \nDemir [B. et](B. et) al: BMI to assess efficacy of nivolumab © Med Sci Monit, 2025; 31: e951296  \nIntroduction  \nNon-small cell lung cancer (NSCLC) is the predominant form of lung cancer, in contrast to small cell lung cancer [1] . Irrespective of new treatments, the ","cbCaihFrunsEf4Ne","https://ap.wps.com/l/cbCaihFrunsEf4Ne","pdf",682813,11,"English","# Background\n## Immune checkpoint inhibitors and nivolumab\n## Rationale for BMI\n# Material/Methods\n## Study design and population\n## Endpoints and statistical analysis\n# Results\n## Survival outcomes by BMI\n## Prognostic factors and treatment effects\n## Treatment response and adverse events\n# Conclusions","[{\"question\":\"What question does the study address about BMI and nivolumab?\",\"answer\":\"The study evaluates whether body mass index (BMI) is associated with treatment efficacy of nivolumab monotherapy in advanced NSCLC patients.\"},{\"question\":\"How were patients selected and what were the primary and secondary endpoints?\",\"answer\":\"The retrospective analysis included 300 metastatic NSCLC patients treated with nivolumab between January 2020 and March 2025. Overall survival was the primary endpoint, with progression-free survival, treatment response, and toxicity as secondary endpoints.\"},{\"question\":\"Did BMI affect overall survival or progression-free survival?\",\"answer\":\"No. Median overall survival and progression-free survival did not differ significantly between BMI groups.\"}]","The Role of Body Mass Index in Determining the Efficacy of Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer | PDF",1790179251,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ec05414d2ac898c0329b5790542ae0e.webp",983,1376,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c30a19cdd746a38d329ed41cc43e87cb.webp",982,1374,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/292bde3fec4607972c9ea77e12664314.webp",981,1373,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c744dee7b41c192e32b4c3fb7055a628.webp",980,1372]